{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:18:25Z","timestamp":1793902705339,"version":"4.8.0"},"reference-count":67,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder with progressive systemic deposition of globotriaosylceramide, leading to life-threatening cardiac, central nervous system, and kidney disease. Current therapy involves symptomatic medical management, enzyme replacement therapy (ERT), dialysis, kidney transplantation, and, more recently, gene therapy. The aim of this systematic review was to assess outcomes of kidney transplantation among patients with FD. Methods: A comprehensive literature review was conducted utilizing MEDLINE, EMBASE, and Cochrane Database, from inception through to 28 February 2020, to identify studies that evaluate outcomes of kidney transplantation including patient and allograft survival among kidney transplant patients with FD. Effect estimates from each study were extracted and combined using the random-effects generic inverse variance method of DerSimonian and Laird. Results: In total, 11 studies, including 424 kidney transplant recipients with FD, were enrolled. The post-transplant median follow-up time ranged from 3 to 11.5 years. Overall, the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 32.5% (95%CI: 23.9%\u201342.5%), 14.5% (95%CI: 8.4%\u201323.7%), and 20.2% (95%CI: 15.4%\u201325.9%), respectively. In the sensitivity analysis, limited only to the recent studies (year 2001 or newer when ERT became available), the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 28.1% (95%CI: 20.5%\u201337.3%), 11.7% (95%CI: 8.4%\u201316.0%), and 20.2% (95%CI: 15.5%\u201326.0%), respectively. The pooled estimated rate of biopsy proven FD recurrence was 11.1% (95%CI: 3.6%\u201329.4%), respectively. There are no significant differences in the risks of all-cause graft failure (p = 0.10) or mortality (0.48) among recipients with vs. without FD. Conclusions: Despite possible FD recurrence after transplantation of 11.1%, allograft and patient survival are comparable among kidney transplant recipients with vs. without FD.<\/jats:p>","DOI":"10.3390\/diseases9010002","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T12:19:51Z","timestamp":1608725991000},"page":"2","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of Kidney Transplantation in Fabry Disease: A Meta-Analysis"],"prefix":"10.3390","volume":"9","author":[{"given":"Maria L. Gonzalez","family":"Suarez","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charat","family":"Thongprayoon","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5041-4290","authenticated-orcid":false,"given":"Panupong","family":"Hansrivijit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA 17105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-1612","authenticated-orcid":false,"given":"Juan","family":"Medaura","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-6722","authenticated-orcid":false,"given":"Pradeep","family":"Vaitla","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1814-7003","authenticated-orcid":false,"given":"Michael A.","family":"Mao","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Bathini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boonphiphop","family":"Boonpheng","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-6665","authenticated-orcid":false,"given":"Swetha R.","family":"Kanduri","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-724X","authenticated-orcid":false,"given":"Karthik","family":"Kovvuru","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0533-4582","authenticated-orcid":false,"given":"Arpita","family":"Basu","sequence":"additional","affiliation":[{"name":"Emory Transplant Center and Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9954-9711","authenticated-orcid":false,"given":"Wisit","family":"Cheungpasitporn","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: A consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s100380170088","article-title":"Fabry disease: Twenty novel alpha-galactosidase A mutations causing the classical phenotype","volume":"46","author":"Ashley","year":"2001","journal-title":"J. Hum. Genet."},{"key":"ref_4","first-page":"227","article-title":"Fabry disease: Twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"Tong","year":"2000","journal-title":"J. Investig. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000472202","article-title":"Fabry disease: Fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries","volume":"4","author":"Davies","year":"1996","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: Thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: Twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s004390050292","article-title":"Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease","volume":"98","author":"Germain","year":"1996","journal-title":"Hum. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Germain, D.P. (2001). A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib. Nephrol., 234\u2013240.","DOI":"10.1159\/000060194"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","article-title":"Fabry disease: Identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches","volume":"257","author":"Germain","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03402156","article-title":"Fabry disease: Twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes","volume":"8","author":"Germain","year":"2002","journal-title":"Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","article-title":"Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease","volume":"197","author":"Ishii","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: Increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00207037","article-title":"Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease","volume":"89","author":"Ishii","year":"1992","journal-title":"Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/3.3.503","article-title":"Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease","volume":"3","author":"Jansen","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"ref_16","first-page":"784","article-title":"Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease","volume":"47","author":"Sakuraba","year":"1990","journal-title":"Am. J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","article-title":"Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype","volume":"76","author":"Shabbeer","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: Identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"Shabbeer","year":"2006","journal-title":"Hum. Genom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF03401993","article-title":"Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease","volume":"5","author":"Topaloglu","year":"1999","journal-title":"Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Shin, S.H., Park, M.H., Byeon, J.J., Lee, B.I., Park, Y., Ko, A.R., Seong, M.R., Lee, S., Kim, M.R., and Seo, J. (2018). A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10020069"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Esposito, R., Russo, C., Santoro, C., Cocozza, S., Riccio, E., Sorrentino, R., Pontillo, G., Luciano, F., Imbriaco, M., and Brunetti, A. (2020). Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092741"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Levstek, T., Vujkovac, B., and Trebusak Podkrajsek, K. (2020). Biomarkers of Fabry Nephropathy: Review and Future Perspective. Genes, 11.","DOI":"10.3390\/genes11091091"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Barba-Romero, M., and Pintos-Morell, G. (2016). Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17121965"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Veroux, M., Monte, I.P., Rodolico, M.S., Corona, D., Bella, R., Basile, A., Palmucci, S., Pistorio, M.L., Lanza, G., and De Pasquale, C. (2020). Screening for Fabry Disease in Kidney Transplant Recipients: Experience of a Multidisciplinary Team. Biomedicines, 8.","DOI":"10.3390\/biomedicines8100396"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Capelli, I., Aiello, V., Gasperoni, L., Comai, G., Corradetti, V., Ravaioli, M., Biagini, E., Graziano, C., and La Manna, G. (2020). Kidney Transplant in Fabry Disease: A Revision of the Literature. Medicina, 56.","DOI":"10.3390\/medicina56060284"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ravarotto, V., Simioni, F., Carraro, G., Bertoldi, G., Pagnin, E., and Cal\u00f2, L.A. (2018). Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?. J. Clin. Med., 7.","DOI":"10.3390\/jcm7110409"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e035182","DOI":"10.1136\/bmjopen-2019-035182","article-title":"Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: Findings from the opinion-based PREDICT-FD modified Delphi consensus initiative","volume":"10","author":"Hughes","year":"2020","journal-title":"BMJ Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lambert, J.R.A., Howe, S.J., Rahim, A.A., Burke, D.G., and Heales, S.J.R. (2019). Inhibition of Mitochondrial Complex I Impairs Release of \u03b1-Galactosidase by Jurkat Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184349"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Duro, G., Zizzo, C., Cammarata, G., Burlina, A., Burlina, A., Polo, G., Scalia, S., Oliveri, R., Sciarrino, S., and Francofonte, D. (2018). Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123726"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jcmg.2020.05.011","article-title":"Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy","volume":"13","author":"Bernardini","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","article-title":"Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: Results from a large multicenter cohort study","volume":"41","author":"Arends","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","article-title":"The kidney in Fabry\u2019s disease","volume":"86","author":"Pisani","year":"2014","journal-title":"Clin. Genet."},{"key":"ref_36","first-page":"203","article-title":"Correction of enzymatic deficiencies by renal transplantation: Fabry\u2019s disease","volume":"72","author":"Desnick","year":"1972","journal-title":"Surgery"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-77-2-195","article-title":"Reversal of an inborn sphingolipidosis (Fabry\u2019s disease) by kidney transplantation","volume":"77","author":"Philippart","year":"1972","journal-title":"Ann. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJM197308022890514","article-title":"Kidney transplantation in Fabry\u2019s disease","volume":"289","author":"Philippart","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"ref_39","first-page":"232","article-title":"Enzyme replacement in genetic disease. Prospectus","volume":"9","author":"Krivit","year":"1973","journal-title":"Birth Defects Orig. Artic. Ser."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/oxfordjournals.ndt.a027338","article-title":"Is there true recurrence of Fabry\u2019s disease in the transplanted kidney?","volume":"11","author":"Peces","year":"1996","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00007890-199104000-00004","article-title":"Recurrence of Fabry\u2019s disease in a renal allograft eleven years after successful renal transplantation","volume":"51","author":"Mosnier","year":"1991","journal-title":"Transplantation"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jama.1975.03250020022018","article-title":"Renal transplantation in congenital and metabolic diseases. A report from the ASC\/NIH renal transplant registry","volume":"232","author":"Barnes","year":"1975","journal-title":"J. Am. Med Assoc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000184389","article-title":"Natural history and treatment of uremia secondary to Fabry\u2019s disease: An European experience","volume":"46","author":"Donati","year":"1987","journal-title":"Nephron"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000059903","article-title":"Renal transplantation in patients with hereditary kidney disease: Our experience","volume":"122","author":"Mazzarella","year":"1997","journal-title":"Contrib. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1016\/j.transproceed.2005.11.021","article-title":"Kidney transplantation improves survival and is indicated in Fabry\u2019s disease","volume":"37","author":"Inderbitzin","year":"2005","journal-title":"Transpl. Proc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","article-title":"Agalsidase therapy in patients with Fabry disease on renal replacement therapy: A nationwide study in Italy","volume":"23","author":"Mignani","year":"2008","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","article-title":"Kidney transplantation in patients with Fabry disease","volume":"22","author":"Cybulla","year":"2009","journal-title":"Transpl. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/TP.0b013e318191a842","article-title":"Kidney transplant outcomes in patients with fabry disease","volume":"87","author":"Shah","year":"2009","journal-title":"Transplantation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry\u2019s disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.ymgme.2015.12.406","article-title":"Beneficial effect of agalsidase beta on long term evolution of patients with Fabry disease and kidney transplant","volume":"117","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_56","first-page":"8S","article-title":"Long-term outcome of kidney transplantation in Fabry disease","volume":"146","author":"Cippa","year":"2016","journal-title":"Swiss Med Wkly."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3904\/kjim.2016.067","article-title":"Outcomes of living donor kidney transplantation in diabetic patients: Age and sex matched comparison with non-diabetic patients","volume":"33","author":"Baek","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_58","first-page":"57","article-title":"Ten-year experience in renal transplantation for Fabry\u2019s disease","volume":"13","author":"Maizel","year":"1981","journal-title":"Transpl. Proc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJM197212142872402","article-title":"Enzyme Replacement Therapy by Renal Allotransplantation in Fabry\u2019s Disease","volume":"287","author":"Clarke","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0888-7543(91)90493-X","article-title":"Structural organization and complete sequence of the human alpha-N-acetylgalactosaminidase gene: Homology with the alpha-galactosidase A gene provides evidence for evolution from a common ancestral gene","volume":"10","author":"Wang","year":"1991","journal-title":"Genomics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"21859","DOI":"10.1016\/S0021-9258(18)45818-8","article-title":"Human \u03b1-N-acetylgalactosaminidase-molecular cloning, nucleotide sequence, and expression of a full-length cDNA: Homology with human \u03b1-galactosidase a suggests evolution from a common ancestral gene","volume":"265","author":"Wang","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_62","first-page":"1499","article-title":"Fabry\u2019s disease: Two patients improved by fetal liver cells (author\u2019s transl)","volume":"8","author":"Touraine","year":"1979","journal-title":"Nouv. Presse Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1097\/TP.0000000000002257","article-title":"Persistent Alpha-galactosidase A Deficiency After Simultaneous Liver-kidney Transplantation in a Patient With Fabry Disease","volume":"102","author":"Likhitsup","year":"2018","journal-title":"Transplantation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Goyal","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J. Intern. Med."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/1\/2\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:44Z","timestamp":1760179724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/1\/2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["diseases9010002"],"URL":"https:\/\/doi.org\/10.3390\/diseases9010002","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]}}}